Abstract
The Epstein-Barr virus (EBV) BNLF2a gene product provides immune evasion properties to infected cells through inhibition of transporter associated with antigen processing (TAP)-mediated transport of antigen peptides. Although BNLF2a is considered to be a lytic gene, we demonstrate that it is expressed in nearly half of the EBV-associated gastric carcinomas analyzed. Further, we show that BNLF2a expression is dissociated from lytic gene expression. BNLF2a is therefore expressed in this latency setting, potentially helping protect the infected tumor cells from immunosurveillance.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.
Publication types
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
MeSH terms
-
ATP-Binding Cassette Transporters / antagonists & inhibitors*
-
Epstein-Barr Virus Infections / immunology*
-
Epstein-Barr Virus Infections / virology*
-
Gene Expression
-
Genes, Viral
-
Herpesvirus 4, Human / genetics*
-
Herpesvirus 4, Human / immunology
-
Histocompatibility Antigens Class I / metabolism*
-
Host-Pathogen Interactions / genetics
-
Host-Pathogen Interactions / immunology
-
Humans
-
Stomach Neoplasms / immunology*
-
Stomach Neoplasms / virology*
-
Tumor Escape
-
Viral Matrix Proteins / genetics*
-
Viral Matrix Proteins / immunology
Substances
-
ATP-Binding Cassette Transporters
-
BNLF21 protein, human herpesvirus 4
-
Histocompatibility Antigens Class I
-
Viral Matrix Proteins
-
transporter associated with antigen processing (TAP)
Associated data
-
GEO/GSE45453
-
GEO/GSE70513